Perspective announces first patient dosed in cohort of Phase 1/2a trial

Perspective Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of 212PbVMT01, a targeted alpha-particle therapy, in patients with previously treated, histologically confirmed metastatic melanoma and positive melanocortin 1 receptor imaging scans. Patients in this cohort are receiving 212PbVMT01 at 3.0 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo. Additionally, the 212PbVMT01 3.0 mCi monotherapy cohort reopened for enrollment. The Safety Monitoring Committee recommended evaluating 212PbVMT01 at a higher dose based on its review of five patients dosed with 212PbVMT01 1.5 mCi monotherapy and two patients dosed with 212PbVMT01 at 1.5 mCi together with nivolumab.